Industry focus on rare cancers means nothing in pipeline for major diseases
By Nicola Garrett
14 Aug 2019
The focus on rare diseases by the pharmaceutical industry is a dangerous trend that is stifling innovation and neglects major causes of death and disability such as cardiovascular disease, the President of the European Society of Cardiology has warned. Speaking at the Cardiac Society of Australia and NZ meeting in Adelaide, Professor Babara Casadei who ...